Our worldwide R&D network of sites includes strategic global hubs in US, UK, Belgium and key expert facilities in Italy and Spain.
Today, 2,000 people are focused on the discovery of vaccines at our Belgium R&D hub, where vaccines have been discovered and developed since 1958.
Our R&D site in Shanghai focuses on Clinical Development.
Heidelberg is home to GSK people discovering and developing medicines for patients.
1000 people work on a variety of R&D functions at our India Global Capability Centre, with our primary site in Bengaluru and satellite sites in Mumbai and Hyderabad.
With a 100-year history, our Siena R&D hub hosts 900 GSK people focused on developing bacterial vaccines and monoclonal antibodies.
Our Akasaka site in Tokyo is a mixed-function site. The R&D focus is on developing medicines and vaccines for patients.
Part of our fast-expanding R&D sites in Poland with 600 people, GSK Poznan is our Global Regulatory Centre, focusing on high quality regulatory services for our medicines.
Part of our fast-expanding R&D sites in Poland with 600 people, GSK Warsaw hosts R&D functions for the discovery of medicines, including leading on pivotal clincical trials.
GSK Jurong is a mixed Global Supply Chain and R&D site. It features clinical and development small molecule manufacturing.
Our Tres Cantos site, where medicines have been discovered and developed for over 25 years, is focused on discovering new therapeutics to prevent infectious diseases.
Our Zug site hosts our oncology facility, with people working across global oncology functions to develop medicines for patients.
Addenbrookes is our primary clinical site for first-time-in-human and experimental medicine trials.
Harlow is a Clinical Trial Supply Packaging and Distribution site, and our primary warehouse in our R&D network.
Our R&D hub in Stevenage is home to more than 2,500 GSK people focused on discovering and developing new medicines.
At our Kings Cross site in London, we’re focused on using artificial intelligence and machine learning to understand the pathway through a disease, which will help to diagnose individual patients more precisely.
At GSK Ware, we specialise in drug product development, with 450 people supporting the development and registration of new medicines.
GSK HQ is our global corporate headquarters and home to 1,000 people working in R&D. All R&D activities at this site are office-based, with a focus across 20 R&D sub-functions.
Our Branford, Connecticut, site is GSK’s sole location for R&D within the ViiV network, focusing on the drug discovery and early development of HIV treatments.
Home to more than 200 colleagues focused on the use of MAPS technology. The site has been designed to offer a holistic and agile approach with all vaccine development in one place: from discovery to manufacturing.
Our people at Cambridge Park Drive focus primarily on early discovery and immunology research.
Our Technology Square site sits at the heart of the Cambridge biotechnology hub and hosts cutting-edge R&D groups.
In downtown Durham, 350 GSK people are working across various R&D functions.
GSK people in Philadelphia are focused specifically on Medical and Regulatory Affairs.
Our Richardson, Texas site is a mixed site with an R&D technology focus.
Our Rockville Center for Vaccines Research hosts 350 people focused on the discovery of new vaccines and technologies
Our south San Francisco site focuses primarily on using artificial intelligence and machine learning to generate data that’s becoming increasingly important in drug discovery.
Our Upper Merion site hosts over 500 people working to discover and develop medicines.
Our largest US-based site, our Upper Providence R&D hub features eight smart labs and 3,000 GSK people discovering and developing new medicines.
Our largest office-based facility in New England, our Waltham site hosts 300 people working in R&D to discover new medicines.
At our Zebulon, North Carolina site, our people are focused on R&D of the Clinical Supply Chain.
